KRAS and neoplasm: KRAS mutation can regulate β‐oxidation of fatty acids in non‐small cell lung cancer (NSCLC) and de novo synthesis processes to participate in tumor metabolic reprogramming and regulate fatty acid metabolic enzymes to regulate fatty acid production in lung cancer cells.17, 18